Also found in: Medical, Encyclopedia, Wikipedia.


Any of a group of DNA viruses of the family Papillomavirus that can cause warts and certain types of cancer in mammals.


(Biology) any of numerous viruses that cause the formation of papillomas


(ˌpæp əˈloʊ məˌvaɪ rəs)

n., pl. -rus•es.
a type of papovavirus, containing circular DNA, that causes papillomas, including genital warts.


n virus m del papiloma papilomavirus m; human — (HPV) virus m del papiloma humano (VPH), papilomavirus humano (PVH)
References in periodicals archive ?
PHYSICIAN RECOMMENDATION was the most common reason parents began human papillomavirus (HPV) vaccination for their adolescents, Brandon Brown, PhD, at the University of California, Riverside, and his associates said.
Urothelial carcinoma with prominent squamous differentiation in the setting of neurogenic bladder: role of human papillomavirus infection.
M2 PHARMA-July 13, 2017-Global Human Papillomavirus Testing Market is to Reach Nearly USD 1.
Human papillomavirus (HPV) belongs to the family Papillomaviridae.
Objective: To determine the rate of acceptance of human papillomavirus vaccine for prevention of cervical cancer, and to identify causes of its low acceptance and means of encouraging its uptake.
Prevalence of E6/E7 oncogenes of Human Papillomavirus (HPV) types 16 and 18 have been studied in cervical cancer patients in Pakistani population.
A Phase 1/2 study of durvalumab alone or in combination with AXAL in recurrent/persistent or metastatic cervical or human papillomavirus (HPV)+ squamous cell cancer of the head and neck (SCCHN): preliminary Phase 1 results.
Global Markets Direct's, 'Human papillomavirus (HPV) Associated Cancer - Pipeline Review, H1 2016', provides an overview of the Human papillomavirus (HPV) Associated Cancer pipeline landscape.
Human papillomavirus (HPV) is one of the most common causes of sexually transmitted diseases in the worldwide.
American College of Pediatricians New Concerns about the Human Papillomavirus Vaccine [Internet].
Healthcare company Merck (NYSE:MRK) reported on Tuesday that it has received US Food and Drug Administration (FDA) approval for an expanded age indication for its 9-valent human papillomavirus (HPV) vaccine, called GARDASIL9 (Human Papillomavirus 9-valent Vaccine, Recombinant), to include males 16 to 26 years of age.
The disease burden of the Human Papillomavirus (HPV) among females and its associated sequelae have been widely studied by social and behavioral science researchers and medical professionals.